CINCINNATI, Ohio — A groundbreaking clinical trial funded by the National Institutes of Health (NIH) HEAL Initiative and conducted through the NIDA Clinical Trials Network has demonstrated that weekly extended-release buprenorphine significantly outperforms daily sublingual treatment for pregnant individuals with opioid use disorder. According to findings published in JAMA Internal Medicine, this multicenter study is the first randomized trial to evaluate extended-release buprenorphine specifically for this vulnerable population. Lead author Dr. John Winhusen of the University of Cincinnati College of Medicine, along with National Institute on Drug Abuse Director Dr. Nora D. Volkow, highlighted the implications of these findings for improving maternal and infant health outcomes. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we curated on this story.
- The trial enrolled 140 pregnant adults with opioid use disorder across multiple U.S. sites.
- Weekly injectable extended-release buprenorphine demonstrated higher rates of illicit opioid abstinence compared to daily sublingual dosing.
- Fewer serious adverse events were reported with extended-release treatment.
- Neonatal opioid withdrawal syndrome (NOWS) outcomes did not differ significantly between treatment groups.
- This study is the first randomized trial specifically testing extended-release buprenorphine for opioid use disorder during pregnancy.
Additional Details Reported
The study addresses a critical gap in addiction medicine for pregnant individuals, who have historically faced limited medication-assisted treatment options. Buprenorphine is already considered the standard of care for opioid use disorder during pregnancy, but adherence to daily sublingual dosing can be challenging for many patients. The extended-release formulation, administered via weekly injection, offers a potential solution to medication adherence concerns while maintaining treatment efficacy.
The finding that neonatal outcomes did not differ between groups is particularly significant, as it suggests that the extended-release formulation provides comparable safety for infants while offering improved maternal outcomes. Neonatal opioid withdrawal syndrome remains a concern for infants exposed to opioids in utero, regardless of the specific formulation used by the mother.
The NIH HEAL Initiative, which funded this research, continues to support studies aimed at addressing the opioid crisis through improved prevention and treatment strategies. The NIDA Clinical Trials Network’s multicenter approach ensured diverse geographic representation and enhanced the generalizability of findings.
How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.